文献速递肿瘤 PET/CT

68Ga-FAPI-46与18F-FDG PET/CT在头颈部鳞状细胞癌评估中的头对头比较:单中心探索性研究

Head-to-Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT for Evaluation of Head and Neck Squamous Cell Carcinoma: A Single-Center Exploratory Study.
PubMed 文献 · J Nucl Med · 2021-12-02

该单中心探索性研究纳入分别接受初始分期(12例)和复发检测(28例)的头颈部鳞状细胞癌患者,比较68Ga-FAPI-46与18F-FDG PET/CT的检出一致性、诊断准确性和半定量参数。68Ga-FAPI-46在初始分期和复发检测中与18F-FDG的一致性分别为83.3%和96.4%,基于病灶分析两者灵敏度均为100%、特异度均为50%、准确率均为94.4%;FAP表达肿瘤体积大于代谢肿瘤体积(P<0.05),其余参数无显著差异。

要点

  • 68Ga-FAPI-46与18F-FDG PET/CT在初始分期和复发检测中一致性分别为83.3%和96.4%。
  • 基于18个组织病理学验证病灶,两种示踪剂灵敏度均为100%、特异度均为50%、准确率均为94.4%。
  • FAP表达肿瘤体积大于代谢肿瘤体积(P<0.05),其余半定量参数无显著差异。

核心结论

  • 68Ga-FAPI-46 PET/CT在头颈部鳞状细胞癌初始分期和复发检测中与18F-FDG PET/CT显示良好一致性,诊断性能相当。

研究设计与样本

  • 单中心探索性研究纳入12例头颈部鳞状细胞癌患者行初始分期、28例患者行复发检测,分别接受68Ga-FAPI-46与18F-FDG PET/CT检查。
  • 分析两种示踪剂的一致性和诊断准确性,比较SUVmax、SUVmean、肿瘤/本底比值等半定量参数,采用配对t检验分析差异。

主要发现

  • 68Ga-FAPI-46 PET/CT与18F-FDG PET/CT在初始分期中的一致性为83.3%,在复发检测中的一致性为96.4%。
  • 18个病灶经组织病理学验证,两种示踪剂基于病灶分析的灵敏度均为100%、特异度均为50%、准确率均为94.4%。
  • FAP表达肿瘤体积大于代谢肿瘤体积(P<0.05),其余半定量参数未见显著差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

68Ga-conjugated fibroblast activation protein inhibitor (68Ga-FAPI) has become an attractive agent for PET. This study aimed to compare 68Ga-FAPI-46 PET/CT with 18F-FDG PET/CT for detecting primary cancer and metastatic lesions in patients with head and neck squamous cell carcinoma (HNSCC). Methods: Twelve patients and 28 patients with HNSCC underwent 68Ga-FAPI-46 and 18F-FDG PET/CT for initial staging and recurrence detection, respectively. The concordance and diagnostic accuracy of both tracers were analyzed. Semiquantitative parameters, including SUVmax, SUVmean, and tumor-to-background ratio, were compared. Fibroblast activation protein (FAP) expression tumor volume and total lesion FAP expression of 68Ga-FAPI-46 were compared with metabolic tumor volume and total lesion glycolysis of 18F-FDG, respectively. Differences between semiquantitative parameters were analyzed using paired t testing. Results:68Ga-FAPI-46 PET/CT was 83.3% and 96.4% concordant with 18F-FDG PET/CT for initial staging and recurrence detection, respectively. Eighteen lesions had histopathologic validation, and both tracers displayed 100% sensitivity, 50% specificity, and 94.4% accuracy for lesion-based analysis. FAP expression tumor volume was greater than metabolic tumor volume (P < 0.05), but no significant differences were observed for the other parameters. Conclusion:68Ga-FAPI-46 PET/CT showed good concordance with, and comparable diagnostic performance to, 18F-FDG PET/CT for initial staging and recurrence detection in HNSCC patients.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Promteangtrong C, Siripongsatian D, Jantarato A, et al. Head-to-Head Comparison of 68Ga-FAPI-46 and 18F-FDG PET/CT for Evaluation of Head and Neck Squamous Cell Carcinoma: A Single-Center Exploratory Study. J Nucl Med. 2021. PMID: 34857655. doi:10.2967/jnumed.121.262831

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。